- Intercept Pharmaceuticals (ICPT): Q4 EPS of -$0.64 beats by $0.06.
- Revenue of $405K (flat Y/Y) misses by $485K.
- Says it expects to be able to fund operations into Q3 2015 based upon currently expected level of program commitment and expected operating expenditures.
- Shares -13.6% AH.
- Press release
Next headline on your portfolio: